Objective: The increasing incidence of new-onset seizures with age is well known. Often, the etiology cannot be clarified. In the present study, patients with unprovoked late-onset seizures and without known neoplasm, who might have had paraneoplastic encephalitis, were investigated for a potentially underlying autoimmunity. Methods: Sixty-six consecutive patients (36 women; aged ≥55 years) after having at least one seizure or seizures for ≤6 months were prospectively identified over a period of 4.75 years. All patients were tested for serum and cerebrospinal fluid (CSF) antibodies (Abs) to both neural cell-surface and intracellular antigens. Forty-five (68%) underwent brain magnetic resonance imaging (MRI). Follow-up in Ab-positive cases was ≥6 months. Results: Two patients had high titers of anti-CASPR2 (contactin-associated proteinlike 2) Abs in serum and CSF and fulfilled the diagnostic criteria of definite limbic encephalitis. Another two patients had bilateral encephalitic temporal MRI abnormalities. They also satisfied the criteria of definite limbic encephalitis, even though they had no Abs in serum or CSF. All four were in the age range of 55-70 years. They received immunotherapy and/or antiepileptic drug treatment and became seizurefree. Significance: Our findings suggest that autoimmunity should be considered an important etiology in patients with late-onset seizures. Testing for neural antibodies and brain MRI may be worthwhile in this patient group.
Frequently, it manifests as limbic encephalitis (LE). LE is clinically characterized by subacute onset of short-term memory deficits, psychiatric symptoms related to the limbic system, and seizures. 4 Mesiotemporal hyperintense T 2 -weighted fluid-attenuated inversion recovery (T 2 /FLAIR) signal, cerebrospinal fluid (CSF) abnormalities and temporal lobe electroencephalography (EEG) abnormalities are common. 5 Until about 2000, almost all LE cases were considered paraneoplastic in origin. 6 Subsequently, non-paraneoplastic forms were identified. 7, 8 Today, nonparaneoplastic LE is considered to predominate over the paraneoplastic manifestations. Antibodies (Abs) directed against neural antigens like contactin-associated proteinlike 2 (CASPR-2), leucine-rich glioma inactivated 1 (LGI1) protein, 4, 9 a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, 10 Glycine receptors (GlyRs), 11 Dipeptidyl-peptidase-like protein-6 (DPPX), 12 metabotropic glutamate receptor 5 (mGlu5), 13 and c-aminobutyric acid B receptor (GABA B R), 14 or glutamic acid decarboxylase (GAD) 15 support this diagnosis. The relevance of autoimmunity in the development of late-onset seizures is still unclear, in particular, in the subgroup of nonlesional cases, that accounts for about 25-45% of epilepsies in the elderly. 4, 16 Therefore, the aim of this study was to investigate the role of autoimmunity in a cohort of patients with nonlesional lateonset seizures and no history of paraneoplasia. Patients with autoimmune etiology should be characterized regarding their MRI characteristics, CSF profiles, EEG characteristics, and outcome.
Materials and Methods
We conducted a prospective single-center observational study. Patients were treated according to the standard of best medical care. All data were obtained during clinical routine, and there were no investigations for the sake of the study.
Patients
The local institutional review board approved this study. Between April 2011 and January 2016, all patients newly diagnosed with late-onset nonlesional seizures (≥55 years of age), and with no history of tumor, at the university hospital of Greifswald/Germany (serving a population of about 300,000 people) were studied. This hospital is the only one providing neurologic care in the entire catchment area. Therefore, it can be assumed that all patients with new-onset seizures were referred to this center.
Patients ≥55 years with one single seizure, one status epilepticus, or seizures for ≤6 months were included unless they had the following: (1) a potentially epileptogenic lesion on brain imaging (computer tomography [CT] or MRI [1.5 or 3 Tesla], if possible) except for lesions that are consistent with the diagnosis of LE, defined as T 2 /fluid-attenuated inversion recovery (FLAIR) hyperintense signal alterations prominently in the mesial temporal lobes including the hippocampus and amygdala; or (2) a history of a neoplastic condition or an onconeural antibody (to exclude paraneoplasia).
Clinical data were collected by reviewing the medical records and during the patient interview. It was noted if a patient presented with the first (known) seizure or after repeated seizures (given they occurred >24 h apart). 1 The clinical impression at first investigation regarding cognitive impairment and depression was noted. The following paraclinical data were documented: routine EEG (International 10-20-system of electrode placement), brain imaging, and CSF studies (CSF cell count and oligoclonal bands [OCB] were recorded for the purposes of this study). Serum and CSF from all patients were tested for Abs against GAD65, NMDAR (N-methyl-D-aspartate receptor), GABA B R, AMPAR1/2, DPPX, mGluR5, LGI1, CASPR2, voltagegated potassium complex (VGKCc) antigens, GlyRs, and atypical Abs against neuropil. The following methods were used: (1) 18, 19 and antibodies against mouse neuropil not reactive with one of the specific cell based assays. 20 Three-month follow-up (if available) and most recent follow-up (≥12 months) in patients with the diagnosis of an autoimmune etiology were evaluated. This comprised assessment of seizure outcome, neuropsychological evaluation, brain imaging, EEG, and serum and CSF collection (if performed). Immunosuppressive therapy (IT) and/or antiepileptic drug (AED) treatment were initialized at the discretion of the treating physician. Patients were screened for tumors, including CT scan of the thorax/abdomen and gynecologic/ urologic investigations, in cases of suspected LE.
The identification of patients occurred in a prospective manner. The diagnoses were made in retrospect. A definite autoimmune etiology was diagnosed for the purposes of this study according to a recent consensus publication using clinical, paraclinical, and serologic data. 5 A definite diagnosis of LE was made in these new-onset patients if the following was present:
1. Bilateral brain abnormalities on T 2 /FLAIR MRI highly restricted to the mesial temporal lobes. 2. At least one of the following:
i. CSF pleocytosis (white blood cell count of >5 cells/ mm³). ii. EEG with epileptic or slow-wave activity involving the temporal lobes. 3. Reasonable exclusion of alternative causes. 4. The detection of an antibody against cell-surface or synaptic proteins could replace one of these.
The clinical criterion of the consensus paper ("Subacute onset [rapid progression of less than 3 months] of working memory deficits, seizures, or psychiatric symptoms suggesting involvement of the limbic system") was replaced by our criterion of new-onset seizures. 5 The second category comprises the inconclusive cases: with neural antibodies of unknown specificity or with unilateral potentially encephalitic mesiotemporal T 2 /FLAIR hyperintense abnormalities but no Abs.
The remainder was labeled not autoimmune in origin.
Five nonparametric Kruskal-Wallis tests for intergroup comparisons were performed. p-Values ≤0.05 were considered significant. We corrected for multiple testing by setting the threshold of significance to ≤0.01.
Results
Of 97 patients screened, 66 patients (36 women) were eligible. Their clinical data are summarized in Table 1 ; details are given in Table S1 of the Supporting Information. Thirtyone patients were excluded for the following reasons: misdiagnosis or a subsequently emerging earlier epilepsy onset (N = 11), tumor and thereby potentially a paraneoplastic condition (N = 18), or symptomatic cause of their seizures (one subdural hematoma, one cerebral infarction); no patient had onconeural antibodies. Twenty-one of the included patients (32%) did not undergo MRI scanning but only cranial CT, mostly due to intracorporal metallic objects or insufficient information on potential implants excluding them from MRI scan.
Definite autoimmune group
Four patients (6%) met the criteria for a definite autoimmune origin. All had definite LE; alternative diagnoses were appropriately ruled out (details are given in Tables 2 and 3) :
Two male patients (1 and 2) had several seizures within 5 weeks (patient 1) and 1 day (patient 2), respectively. Although their initial MRI studies were normal, they had EEG slowing involving one temporal lobe, and in one case an elevated CSF count. Both patients were started on AED treatment and immunotherapy (patient 1: methylprednisolone 500 mg/day for 5 days followed by five cycles of plasma exchange; patient 2: prednisolone 80 mg/day for 4 weeks, subsequently slowly tapered to 10 mg/day over a period of 7 weeks). Initial neuropsychological deficits (patient 1: pronounced verbal and figural memory deficits, attentional deficits, psychomotor slowing; patient 2: mild memory deficits as well as mild depressive disorder) improved significantly with IT and AED treatment in both patients.
The other two female patients (3 and 4) had seizures for 1 day (patient 3) and 3 weeks (patient 4). Both had bilateral mesial temporal signal increase on T 2 -weighted FLAIR at disease onset (Fig. 1B) , but no Abs in serum or CSF. Patient 4 had intermittent slowing and sharp waves on the right temporal lobe lateralizing to the side of maximum MRI abnormalities. She presented with significant neuropsychological deficits (verbal and figural memory deficits). Patient 3 was similarly affected in her cognition; she had additional extensive attentional deficits. Patient 3 was started on IT (methylprednisolone 500 mg/d for 5 days followed by prednisolone 80, descending dosage) and AED treatment and was seizure-free at 3-month follow-up. Neuropsychological deficits improved moderately. Patient 4 declined IT, was started on AED treatment, and became seizure-free only on addition of a second AED. Memory deficits resolved quickly and were no longer detectable after 3 months; 3-month follow-up MRI had normalized, too.
Inconclusive group
Seven patients (11%) fell into this category (for details see Table 4 ): (1) Four patients with low serum titers of CASPR2 antibodies or VGKCc antibodies not reactive with LGI1 or CASPR2 (patients I and II) or neuropil Abs (patients III and IV), one of them in both serum and CSF (patient IV). Patient III had a normal initial MRI and became seizure-free at 15-month follow-up on treatment with levetiracetam. Patient IV with nonspecific neuropil Abs in both serum and CSF had a right hippocampal hyperintense T 2 /FLAIR signal as well as pronounced neuropsychological deficits (memory impairment, attentional deficits, and psychomotor slowing); this patient became seizure-free under IT (prednisolone 80, descending dosage). (2) Three patients presented with unilateral mesial temporal hyperintense T 2 /FLAIR signal (all of them left-sided) but no neural Abs: Patient V had elevated CSF cell count and was treated with acyclovir, ampicillin, and ceftriaxone for 2 weeks; this patient became seizure-free at follow-up (9 months) with the second AED (levetiracetam). Patient VI was treated with prednisolone 80 mg/day (descending dosage) and a combination of levetiracetam and oxcarbazepine, but had ongoing seizures at 24-month follow-up; MRI at follow-up showed left-sided hippocampal atrophy. Patient VII presented with normal CSF, but had an elevated CSF cell count at 5-month follow-up. He was treated with acyclovir and, subsequently, with prednisolone (80 mg/day, descending dosage). Follow-up MRI showed left-sided hippocampal atrophy; the patient was not seizure-free despite adequate AED treatment (Fig. 1C) . (Table 3 , patient 2, MRI 3 months after seizure onset, definite autoimmune origin). B. Hyperintensity, bilateral mesial temporal; left > right; Ab-negative (Table 2 , patient 4, MRI at disease onset, definite autoimmune origin). C. Hyperintensity and atrophy left hippocampus; Ab-negative ( 
Nonautoimmune group
The presumed etiologies in this group of 55 patients were vascular (N = 7), degenerative (N = 6), combined vascular and degenerative (N = 12), and unknown (N = 30).
Intergroup comparison
Patients with definite autoimmune origin were the youngest; the nonimmune were the oldest with the inconclusive patients lying in-between (p = 0.0079). The other significant difference between the groups was the frequency of depression (definite autoimmune, 50%; inconclusive, 0%; not autoimmune, 4%; p = 0.008). Sex distribution, single versus multiple seizures at presentation, and cognitive impairment were not different across the three groups.
Discussion
The goal of this prospective, observational populationbased cohort study was to investigate the proportion of definite autoimmune-mediated new-onset seizures in a cohort of patients ≥55 years of age. The study was done in an emergency department and was population based. This age group was chosen because approximately at this age, the incidence curve of unprovoked seizures starts rising. 1, 2 In our sample, 6% of the cases had an autoimmune origin, more specifically, limbic encephalitis.
Our results suggest that autoimmunity is one relevant etiology in patients with late-onset epilepsy and should be considered when planning individual diagnostic measures. Patients between 55 and 65 years and those with depression have a higher risk of having an autoimmune origin; all definite autoimmune patients had cognitive impairment (but this was not significantly different when comparing the three groups). In our sample, CASPR2 antibody positivity at high titers and bilateral mesiotemporal T 2 /FLAIR hyperintense signals were the relevant diagnostic clues. The clinical spectrum of symptoms related to Abs against CASPR2, a membrane protein expressed in the peripheral and central nervous system (PNS, CNS), is well defined. 17, 21, 22 Cognitive disturbances and epileptic seizures are reported to be the most common initial CNS symptoms. 22 Joubert et al. 23 reported CASPR2 Abs in CSF to be associated with prominent limbic symptoms and temporal lobe epilepsy and rarely with neoplasm, compared to PNS symptoms among cases with CASPR2 Abs in serum only. This raises the question that if the clinical presentation at disease onset can help to distinguish between Ab-positive and Ab-negative cases and might impact the decision, should testing for Abs in serum and/or CSF be part of the individual diagnostic protocol. One should note that the present study considered patients with a newly diagnosed seizure disorder and not those with other core symptoms of LE. However, encephalopathy findings like confusion or cognitive impairment are rather infrequent in the acute phase of CASPR2-positive encephalitis (compared to LGI1-positive encephalitis) 24, 25 and symptoms are milder compared to other autoimmune encephalopathies. 22 In addition, the same group found a clinical evolution of the symptoms over 1 year in about one third of their CASPR2 Ab-positive patients. The delayed development of mesial temporal MRI abnormalities in our patients is in line with this observation. Other Abs known to occur in the studied age group are those against LGI1 or the GABA B R, to mention only two most frequent ones besides CASPR2 Abs.
Upon immunotherapy (N = 3) and AED therapy (N = 4), all patients with definite autoimmune origin became seizure-free and showed cognitive improvement. In the two cases with CASPR2 Abs, clinical improvement correlated with reduction in Ab titers in serum/CSF, as reported previously. 26, 27 There is an inconclusive group (11% of the sample) that in several aspects lies in between the group with definite autoimmune origin and the nonautoimmune group. It may be that in some of these patients, autoimmunity contributes to the conditions but this is not clear on an individual level. Four patients had neural antibodies of doubtful specificity, and the other three had unilateral mesiotemporal signal increases without clear alternative explanation. The latter, however, can also be observed in nonimmune disorders and even occur because of seizures themselves. Even though there are definite cases with limbic encephalitis and unilateral MRI abnormality (when a specific antibody is found), the MRI feature alone is not specific for this diagnosis. 5 Three received immunotherapy, and only one of these patients became seizure-free. In the other patients, the treating physicians were not convinced that immunotherapy was indicated and administered antiepileptic medication only. In the total group, only three (43%) of seven became seizurefree.
Limitations
Several limitations of our single-center study need to be considered. First, given the relatively small group of 66 patients, the possibility of type 2 statistical errors that limit statistical validity should be considered. Second, our follow-up of ≥6 months is relatively short. Assuming a certain risk for tumor development for up to 5 years after LE diagnosis, the proportion of non-paraneoplastic Ab-positive patients in our study may be too high. Finally, 32% of our patients had no MRI (most of them because of intracorporal metallic objects). This may have led to an underestimation of definite autoimmune cases. Future, ideally formal prospective studies are therefore expected to challenge and to refine our results.
Conclusion
Both cerebral MRI and panel-testing for Abs targeting neural antigens should be considered in the diagnostic protocol of patients with late-onset seizures and no obvious alternative explanation, as a considerable proportion (in our series: 6%) are positive by one of these domains, leading to the diagnosis of a definite autoimmune etiology with promising results on immunologic and AED therapy. The Graus criteria are helpful for identifying definite cases of LE, even in the absence of a specific neural antibody. Younger patients and patients with concomitant depression (and, though not significant, with concomitant cognitive impairment) are at higher risk of having an autoimmune basis of new-onset seizures.
